Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents.
Restenosis is the principal drawback of percutaneous coronary procedures. Until now, the only widely accepted way to reduce restenosis rate has been the stent. However, clinical restenosis still represents the major limitation of this technology. This article summarizes recent laboratory and clinical investigations concerning the mechanisms responsible for the transmission of mitogenic signals from plasma membrane to the nucleus in vascular smooth muscle cells that determine neointima formation after stent deployment. Recent experimental data on the impact of diabetes and physical exercise on restenosis also is reviewed. Finally, the new concept of local drugs that elute directly to the site of vascular injury from coated stents and the available clinical results obtained with rapamycin or paclitaxel-eluting stents are discussed.
Indolfi
Ciro
C
Division of Cardiology, Magna Graecia University, Catanzaro, Italy. indolfi@unicz.it
Mongiardo
Annalisa
A
Curcio
Antonio
A
Torella
Daniele
D
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D023903:Coronary Restenosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology; D015607:Stents
D020099:Coated Materials, Biocompatible